| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 32 | 2024 | 2898 | 2.870 |
Why?
|
| Neoplasm Metastasis | 25 | 2022 | 1056 | 2.490 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 8 | 2023 | 1075 | 1.610 |
Why?
|
| Immunotherapy | 10 | 2023 | 629 | 1.520 |
Why?
|
| Lung Neoplasms | 11 | 2023 | 2262 | 1.420 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2021 | 592 | 1.380 |
Why?
|
| Mucin-1 | 9 | 2020 | 44 | 1.310 |
Why?
|
| Radiosurgery | 9 | 2024 | 272 | 1.290 |
Why?
|
| Liver Neoplasms | 8 | 2024 | 736 | 1.080 |
Why?
|
| Radioimmunotherapy | 3 | 2021 | 25 | 1.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 13 | 2020 | 1197 | 1.000 |
Why?
|
| Biomarkers, Tumor | 7 | 2021 | 1464 | 0.970 |
Why?
|
| Radiotherapy | 3 | 2020 | 328 | 0.920 |
Why?
|
| Cooperative Behavior | 1 | 2023 | 174 | 0.860 |
Why?
|
| Neoplasm Invasiveness | 2 | 2024 | 552 | 0.830 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 383 | 0.830 |
Why?
|
| Urinary Bladder | 1 | 2024 | 246 | 0.820 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2023 | 98 | 0.810 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 42 | 0.810 |
Why?
|
| Patient Care Team | 1 | 2023 | 280 | 0.790 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 104 | 0.790 |
Why?
|
| Colorectal Neoplasms | 6 | 2023 | 938 | 0.720 |
Why?
|
| Homologous Recombination | 2 | 2017 | 51 | 0.700 |
Why?
|
| Combined Modality Therapy | 12 | 2024 | 1686 | 0.680 |
Why?
|
| Humans | 69 | 2024 | 86643 | 0.680 |
Why?
|
| Gene Amplification | 1 | 2018 | 131 | 0.630 |
Why?
|
| Janus Kinase 2 | 1 | 2018 | 57 | 0.630 |
Why?
|
| STAT1 Transcription Factor | 4 | 2009 | 52 | 0.620 |
Why?
|
| Pyrrolidines | 1 | 2018 | 58 | 0.620 |
Why?
|
| Anthracyclines | 1 | 2017 | 37 | 0.590 |
Why?
|
| Neoplasm, Residual | 2 | 2017 | 162 | 0.580 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 250 | 0.550 |
Why?
|
| Sulfonamides | 1 | 2018 | 300 | 0.540 |
Why?
|
| Prostatic Neoplasms | 5 | 2021 | 1721 | 0.540 |
Why?
|
| Breast Neoplasms | 7 | 2017 | 2903 | 0.520 |
Why?
|
| MicroRNAs | 5 | 2023 | 534 | 0.490 |
Why?
|
| Drug Therapy | 1 | 2014 | 70 | 0.470 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 589 | 0.470 |
Why?
|
| Prognosis | 10 | 2021 | 3679 | 0.470 |
Why?
|
| Cell Line, Tumor | 15 | 2020 | 2426 | 0.460 |
Why?
|
| Radiation Tolerance | 3 | 2019 | 168 | 0.460 |
Why?
|
| DNA Repair | 2 | 2022 | 356 | 0.460 |
Why?
|
| Radiation, Ionizing | 5 | 2021 | 121 | 0.440 |
Why?
|
| Capecitabine | 2 | 2024 | 96 | 0.400 |
Why?
|
| Signal Transduction | 10 | 2023 | 3241 | 0.370 |
Why?
|
| Neovascularization, Pathologic | 1 | 2012 | 353 | 0.370 |
Why?
|
| Endothelium, Vascular | 1 | 2012 | 435 | 0.370 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 930 | 0.360 |
Why?
|
| Gene Expression Profiling | 8 | 2020 | 1384 | 0.360 |
Why?
|
| Mutation | 2 | 2018 | 3968 | 0.360 |
Why?
|
| Animals | 28 | 2023 | 26582 | 0.350 |
Why?
|
| Mice | 19 | 2023 | 11352 | 0.350 |
Why?
|
| Aged | 12 | 2024 | 18415 | 0.350 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2009 | 79 | 0.350 |
Why?
|
| Chemoradiotherapy | 3 | 2021 | 301 | 0.340 |
Why?
|
| Lipid Metabolism | 1 | 2009 | 196 | 0.310 |
Why?
|
| Energy Metabolism | 1 | 2009 | 271 | 0.310 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 2360 | 0.300 |
Why?
|
| Gene Regulatory Networks | 2 | 2009 | 296 | 0.300 |
Why?
|
| Survival Rate | 5 | 2021 | 1863 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2018 | 49 | 0.300 |
Why?
|
| Inflammation | 1 | 2012 | 920 | 0.290 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 860 | 0.280 |
Why?
|
| Neoplasms, Experimental | 3 | 2019 | 269 | 0.280 |
Why?
|
| Middle Aged | 13 | 2023 | 25028 | 0.280 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 458 | 0.270 |
Why?
|
| Genomic Instability | 2 | 2017 | 79 | 0.260 |
Why?
|
| Mice, Nude | 5 | 2020 | 790 | 0.260 |
Why?
|
| DNA Replication | 2 | 2017 | 164 | 0.260 |
Why?
|
| Brain Mapping | 1 | 2008 | 548 | 0.260 |
Why?
|
| Emotions | 1 | 2008 | 341 | 0.250 |
Why?
|
| Male | 16 | 2023 | 40965 | 0.250 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 1673 | 0.240 |
Why?
|
| Female | 17 | 2023 | 44532 | 0.240 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2023 | 17 | 0.240 |
Why?
|
| Neoplasm Staging | 4 | 2023 | 1939 | 0.240 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 6509 | 0.230 |
Why?
|
| Cognition | 1 | 2008 | 570 | 0.230 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 69 | 0.230 |
Why?
|
| Cystectomy | 1 | 2024 | 102 | 0.220 |
Why?
|
| DNA Methylation | 2 | 2018 | 628 | 0.220 |
Why?
|
| Adult | 8 | 2021 | 25648 | 0.220 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2012 | 683 | 0.220 |
Why?
|
| Radiation Pneumonitis | 1 | 2022 | 21 | 0.220 |
Why?
|
| Interferon Type I | 2 | 2021 | 175 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1313 | 0.210 |
Why?
|
| Epigenesis, Genetic | 2 | 2023 | 479 | 0.210 |
Why?
|
| NF-kappa B | 2 | 2023 | 444 | 0.200 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 301 | 0.200 |
Why?
|
| Retrospective Studies | 4 | 2023 | 8489 | 0.200 |
Why?
|
| Light | 1 | 2022 | 289 | 0.200 |
Why?
|
| Cisplatin | 1 | 2024 | 612 | 0.200 |
Why?
|
| Cell Proliferation | 4 | 2018 | 1578 | 0.200 |
Why?
|
| Apoptosis | 5 | 2018 | 1683 | 0.200 |
Why?
|
| Erythroid Precursor Cells | 1 | 2021 | 32 | 0.200 |
Why?
|
| Butyrates | 1 | 2021 | 42 | 0.190 |
Why?
|
| Pneumonia | 1 | 2022 | 179 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 3 | 2018 | 1041 | 0.190 |
Why?
|
| Adenocarcinoma | 3 | 2016 | 1169 | 0.190 |
Why?
|
| Disease Progression | 3 | 2020 | 1531 | 0.190 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2020 | 73 | 0.190 |
Why?
|
| Neuroendocrine Tumors | 1 | 2022 | 105 | 0.190 |
Why?
|
| Cell Survival | 4 | 2019 | 969 | 0.180 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2020 | 28 | 0.180 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 2 | 2018 | 55 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2020 | 120 | 0.170 |
Why?
|
| DEAD Box Protein 58 | 2 | 2016 | 11 | 0.170 |
Why?
|
| Colonic Neoplasms | 2 | 2015 | 556 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 3640 | 0.170 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 252 | 0.170 |
Why?
|
| Treatment Outcome | 7 | 2021 | 7993 | 0.170 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 689 | 0.170 |
Why?
|
| Class II Phosphatidylinositol 3-Kinases | 1 | 2018 | 8 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 123 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 645 | 0.160 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 384 | 0.160 |
Why?
|
| Brain | 1 | 2008 | 2216 | 0.160 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 85 | 0.160 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 77 | 0.160 |
Why?
|
| Interferon-beta | 2 | 2016 | 125 | 0.150 |
Why?
|
| Neuronal Plasticity | 1 | 2020 | 187 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 2438 | 0.150 |
Why?
|
| Palliative Care | 1 | 2019 | 257 | 0.150 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 1195 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 236 | 0.150 |
Why?
|
| DNA Damage | 2 | 2017 | 366 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 7 | 2021 | 3092 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2017 | 91 | 0.150 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2017 | 64 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 645 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 407 | 0.140 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 17 | 0.130 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2015 | 41 | 0.130 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 154 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 1376 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 455 | 0.130 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 236 | 0.120 |
Why?
|
| Prostate | 2 | 2020 | 378 | 0.120 |
Why?
|
| RNA Helicases | 1 | 2014 | 35 | 0.120 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 62 | 0.120 |
Why?
|
| Quality of Life | 1 | 2021 | 1585 | 0.110 |
Why?
|
| Hospitalization | 1 | 2018 | 849 | 0.110 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 2232 | 0.110 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2012 | 63 | 0.110 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2012 | 26 | 0.110 |
Why?
|
| Stress, Physiological | 1 | 2014 | 227 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2022 | 4213 | 0.110 |
Why?
|
| Endothelial Cells | 2 | 2012 | 428 | 0.110 |
Why?
|
| Heterografts | 3 | 2018 | 98 | 0.110 |
Why?
|
| Ipilimumab | 2 | 2022 | 58 | 0.100 |
Why?
|
| Transcriptional Activation | 2 | 2012 | 280 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 2 | 2012 | 144 | 0.100 |
Why?
|
| Myeloid Cells | 2 | 2023 | 98 | 0.100 |
Why?
|
| Melanoma, Experimental | 2 | 2009 | 103 | 0.100 |
Why?
|
| RNA-Binding Proteins | 2 | 2023 | 246 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 469 | 0.100 |
Why?
|
| Interferon-gamma | 4 | 2019 | 444 | 0.090 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 384 | 0.090 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 418 | 0.090 |
Why?
|
| Glioma | 1 | 2012 | 285 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2023 | 70 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 999 | 0.090 |
Why?
|
| Adaptive Immunity | 2 | 2021 | 164 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2009 | 103 | 0.090 |
Why?
|
| X-Ray Therapy | 1 | 2008 | 6 | 0.090 |
Why?
|
| Proteome | 1 | 2009 | 124 | 0.080 |
Why?
|
| Interleukins | 1 | 2009 | 134 | 0.080 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2008 | 94 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 3362 | 0.080 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferase 1 | 2 | 2018 | 18 | 0.080 |
Why?
|
| HCT116 Cells | 2 | 2018 | 151 | 0.080 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 106 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2818 | 0.070 |
Why?
|
| Neoplasm Transplantation | 3 | 2016 | 391 | 0.070 |
Why?
|
| Cholesterol | 1 | 2009 | 356 | 0.070 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 185 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2008 | 342 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 559 | 0.070 |
Why?
|
| Mice, Knockout | 3 | 2019 | 1924 | 0.070 |
Why?
|
| Recurrence | 1 | 2009 | 1139 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 532 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2016 | 252 | 0.070 |
Why?
|
| Cell Movement | 2 | 2019 | 758 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 1540 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 859 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2024 | 155 | 0.060 |
Why?
|
| Methylation | 1 | 2023 | 251 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 46 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2023 | 556 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 72 | 0.050 |
Why?
|
| Metastasectomy | 1 | 2020 | 9 | 0.050 |
Why?
|
| Vancomycin | 1 | 2021 | 72 | 0.050 |
Why?
|
| Aurora Kinase A | 1 | 2020 | 9 | 0.050 |
Why?
|
| Synaptophysin | 1 | 2020 | 11 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 150 | 0.050 |
Why?
|
| POU Domain Factors | 1 | 2020 | 8 | 0.050 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2020 | 15 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 144 | 0.050 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2020 | 21 | 0.050 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2020 | 36 | 0.050 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2020 | 35 | 0.050 |
Why?
|
| RNA | 1 | 2023 | 560 | 0.040 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2020 | 93 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 684 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 751 | 0.040 |
Why?
|
| Rats | 3 | 2010 | 3990 | 0.040 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 191 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2009 | 88 | 0.040 |
Why?
|
| Cell Line | 2 | 2016 | 2468 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 172 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 165 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 266 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 143 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 176 | 0.040 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2020 | 111 | 0.040 |
Why?
|
| Azacitidine | 1 | 2018 | 137 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 56 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2020 | 195 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2018 | 188 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 503 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 937 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 257 | 0.040 |
Why?
|
| RNA, Long Noncoding | 1 | 2018 | 102 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 409 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2020 | 381 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 943 | 0.040 |
Why?
|
| Bacteria | 1 | 2021 | 447 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2023 | 1196 | 0.040 |
Why?
|
| cdc25 Phosphatases | 1 | 2016 | 18 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 468 | 0.040 |
Why?
|
| Remission Induction | 1 | 2018 | 722 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 580 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2016 | 49 | 0.040 |
Why?
|
| RNA, Small Untranslated | 1 | 2016 | 14 | 0.040 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2016 | 11 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2020 | 359 | 0.030 |
Why?
|
| Patient Safety | 1 | 2018 | 212 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 536 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2023 | 1565 | 0.030 |
Why?
|
| Phenotype | 2 | 2015 | 2378 | 0.030 |
Why?
|
| Receptors, CXCR3 | 1 | 2015 | 12 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2015 | 57 | 0.030 |
Why?
|
| Wnt Proteins | 1 | 2016 | 123 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1538 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1169 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 865 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 134 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 679 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 133 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 187 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 268 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2023 | 1920 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2009 | 1135 | 0.030 |
Why?
|
| beta Catenin | 1 | 2016 | 251 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 289 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1163 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 547 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 615 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 927 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 579 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2012 | 31 | 0.030 |
Why?
|
| Peptides | 1 | 2016 | 639 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 2261 | 0.030 |
Why?
|
| Glioblastoma | 1 | 2014 | 255 | 0.030 |
Why?
|
| Estradiol | 1 | 2012 | 252 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 5210 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2012 | 233 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 357 | 0.020 |
Why?
|
| Gene Expression | 1 | 2015 | 1284 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2016 | 1458 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2601 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 353 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2009 | 22 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 229 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 3046 | 0.020 |
Why?
|
| Cytotoxins | 1 | 2009 | 15 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2009 | 86 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 3612 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 20 | 0.020 |
Why?
|
| Etanercept | 1 | 2008 | 32 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2009 | 164 | 0.020 |
Why?
|
| Caspases | 1 | 2009 | 155 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2009 | 281 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2008 | 43 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2010 | 345 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2012 | 471 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1456 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2010 | 439 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2009 | 295 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 685 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 763 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 879 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 256 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 363 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 736 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 896 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 728 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 456 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 427 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 1204 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2009 | 729 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 2062 | 0.020 |
Why?
|
| Cytokines | 1 | 2009 | 776 | 0.020 |
Why?
|
| Child | 1 | 2016 | 6927 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 3030 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 977 | 0.010 |
Why?
|
| Lung | 1 | 2009 | 1170 | 0.010 |
Why?
|